Mining for functionality

HiFiBiO's single cell-based platform discovers diverse, functional antibodies

HiFiBiO S.A.S.

Conventional antibody discovery platforms generate a small number of candidates that block a target, and even fewer that can alter the function of target cells. HiFiBiO S.A.S. has a platform that improves the odds of finding a viable therapeutic by rapidly producing large, genetically diverse sets of functional antibodies.

Standard platforms like phage display and hybridoma-based systems select antibodies based primarily on their ability to bind the target antigen. "So if you're looking for antibodies that make

Read the full 776 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers